Share on LinkedInShare on LinkedIn

ARTICLE · 29 JULY 2025

Market Intelligence Thought Leadership Award Winner

Judicial Review Of Assisted Reproductive Technology (Regulation) Act, 2021

Khaitan & Co.
Khaitan & Co.
Contributor
Khaitan & Co.

Khaitan & Co.

Founded in 1911, Khaitan & Co is a heritage law firm that has been a trusted adviser to leading...

View firm profile
Explore more from Khaitan & Co.

Technology in the medical field has evolved over the years and gradually gave birth to alternate reproductive options, by introducing the Assisted Reproductive Technology (Regulation) Act, of 2021 (ART Act).

IndiaTechnology

I. Introduction

Technology in the medical field has evolved over the years and gradually gave birth to alternate reproductive options, by introducing the Assisted Reproductive Technology (Regulation) Act, of 2021 (ART Act). The ART Act marks a significant legislative intervention in India's healthcare landscape. The Act encompasses framework to govern reproductive procedures, ensuring transparency, accountability, liability, and ethical practices in ART clinics/banks. By safeguarding the interests of donors, commissioning parents, and children born through ART, it addresses enduring concerns of exploitation, commercialisation, and regulatory vacuum in the reproductive health sector. This paper attempts to critically analyse the ART Act, by examining its interplay with the Surrogacy (Regulation) Act, of 2021 (Surrogacy Act), and highlights emerging judicial trends shaping the interpretation of these laws, particularly concerning and reproductive rights.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this document does not necessarily reflect the views / position of Khaitan & Co but remain solely those of the author(s). For any further queries or follow up, please contact Khaitan & Co at [email protected].

See more popular content from